Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


February 8, 2001 8 February, 2001

Pheromone Sciences Corp Announces U.S. Clinical Trials


Toronto, Ontario (February 8, 2001) - Pheromone Sciences Corp (CDNX: PHS), today announced plans for a multi-center U.S. based clinical trial of its PSC Fertility Monitor™. The trial will be carried out at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Comprising 140 patients, the trial will compare the efficacy of the PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ to current techniques for detecting fertility and ovulation. Subject to regulatory approval, patient recruitment is scheduled to commence in April and conclude in Q-4.

U.S. clinical trial plans are being undertaken on the heels of positive clinical results obtained from a pilot trial conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The Canadian trial demonstrated that the PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

Commenting on the U.S. trial program Duke University's Dr. Haney stated, "We look forward to being involved in a clinical study that can potentially assist women in better knowing when fertility and ovulation are optimum". Dr. Corson of the Thomas Jefferson University Hospital added, "Obtaining results in line with those at the Toronto General Hospital would point to the PSC Fertility Monitor™ becoming a valuable tool in planning conception."

The PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ offers a new user- friendly option in family planning. The product, housed in a wristwatch-like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ is a proprietary, non- invasive device, which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor and predicts the status of the user as being not-fertile, fertile or ovulating.

"We remain committed to our goal of filing regulatory submissions with the FDA for marketing approval on the PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "In tandem with the clinical trial process we also intend to advance efforts aimed at concluding a strategic alliance for product marketing and distribution rights."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.